Answers are grounded in this paper and cite their sources.
Ischemic stroke remains a common and disabling disease with few proven therapies to improve functional outcome.1 Investigating the risks and benefits of those treatments, mainly IV thrombolysis (IVT) and mechanical thrombectomy, must occur under the constraints of a time-limited window of opportunity.2 Clinicians making time-sensitive therapeutic decisions need data that define best practices based on relevant individual characteristics such as preexisting level of disability.
No takes yet. Share an insight, caveat, or question.
Bahouth et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: